MAPT and Alzheimer disease: Given the multifactorial nature of the disease including various pathological processes, it is difficult to judge whether a compound might be beneficial or detrimental when only one pathological aspect in AD, e.g. Aβ generation or tau hyperphosphorylation, is investigated.